Bard PowerPort Lawsuit Update (July 2026)

Bard PowerPort case acquisition remains one of the more economically compelling mass tort opportunities available to plaintiff firms in 2026, with MDL 3081 in the District of Arizona now exceeding 8,000 filed plaintiffs and bellwether trials actively underway. The claimant pool continues to grow, liability theory against C.R. Bard and parent company Becton Dickinson is supported by a strong internal document record, and the defendant carries substantial financial exposure. For firms evaluating intake and advertising budgets, the central question is whether current entry economics still justify the investment.

The Litigation Landscape: What MDL 3081 Means for Timing and Case Value

In Re: Bard Implanted Port Catheter Products Liability Litigation was consolidated in the District of Arizona under Judge David Campbell in 2023. The MDL now carries more than 8,000 active plaintiffs, which puts it firmly in large-MDL territory. Discovery is active, and bellwether selection is underway. First trials are projected to begin in 2025, with the broader bellwether sequence running into 2026.

That timeline matters enormously for acquisition strategy. Before bellwether verdicts, case values are speculative. After a plaintiff-friendly verdict, values get anchored and settlement negotiations typically accelerate. Firms that have built their inventory before the first verdict are positioned best. Firms that wait until after a verdict often face higher lead costs, more competition, and a tighter window before a global settlement closes intake.

The defendant structure also matters here. C.R. Bard Inc. is the primary manufacturer and designer. Bard Peripheral Vascular and Bard Access Systems are named Bard entities involved in the device's development and distribution. Becton Dickinson acquired C.R. Bard in 2017 for approximately $24 billion and is a co-defendant. That acquisition is significant from a litigation standpoint. BD is a Fortune 500 company with substantial financial resources, and the indemnification and corporate liability questions that flow from that 2017 deal give plaintiffs' attorneys meaningful leverage. BD cannot easily distance itself from Bard's pre-acquisition conduct when internal documents show Bard knew about the degradation problem years before the deal closed. The Cook v. Becton line of arguments around successor liability gives the plaintiff bar a solid foundation to keep BD on the hook for the full damages picture.

No settlement has been announced. That means individual case values remain unset. Early projections from attorneys tracking the MDL suggest cases involving serious injury, catheter embolism to the pulmonary artery, cardiac complications, or surgical intervention, could carry significant individual value once bellwether outcomes establish the damages framework. Cases requiring hospitalization or repeat intervention but without life-threatening sequelae will likely tier lower. Firms building inventory now should be thinking in tiers and qualifying accordingly.

The Defect: Why the Liability Theory Is Unusually Strong

The alleged defect centers on the Chronoflex AL polyurethane material used in the PowerPort catheter. Plaintiffs allege that barium sulfate, added to the catheter to make it radiopaque and visible on imaging, reacts with the Chronoflex polyurethane over time, causing the material to become brittle and fracture. Catheter fragments then migrate into the bloodstream, traveling to the heart, pulmonary arteries, or lungs, where they can cause embolism, thrombosis, infection, or life-threatening cardiac events.

The key piece of evidence supporting this theory is internal Bard documentation showing awareness of the Chronoflex degradation problem before and during the device's widespread use. When internal documents show a manufacturer knew about a failure mode and did not adequately warn physicians or patients, design defect and failure-to-warn claims become much harder to defend. For firms evaluating this tort from a business perspective, that document record is a significant risk-reducer on the liability side of the equation.

Injuries that appear most frequently in the MDL include catheter fracture and fragment embolization, pulmonary artery migration, deep vein thrombosis, cardiac complications, bloodstream infection and sepsis, and the need for surgical or interventional retrieval of fragments. Cases involving device retrieval or open surgical intervention tend to be the most valuable because the damages are concrete, documented, and causally tied to the device failure.

Claimant Pool and Demand: Is There Still Volume to Capture?

The Bard PowerPort has been implanted in patients across every state since its introduction in 1999. The device is used primarily in oncology patients who need long-term venous access for chemotherapy, which means the implant population is large and geographically distributed nationwide. There is no regional concentration. Cancer treatment centers in every major market have used Bard PowerPort devices, and the installed base runs into hundreds of thousands of implants over the device's commercial life.

The MDL currently sits at 8,000 plus cases, but that number almost certainly understates the eventual claimant pool. Many patients who experienced complications had them attributed to other causes, particularly given that the typical PowerPort patient is a cancer patient whose medical picture is already complicated. Misattribution of catheter-related injuries is common, which means there is a meaningful population of potential claimants who have not yet connected their complications to the device. That suppressed demand is one reason lead volume for this tort remains accessible, the awareness curve has not fully played out.

Saturation is moderate but not severe. The tort is not at the frenzied peak-competition stage that characterized Camp Lejeune or some of the earlier mass tort cycles. Firms that move in the next several months, before bellwether verdicts trigger a media wave, will capture cases at better economics than firms that react after the first verdict headline.

Bard PowerPort Case Acquisition Economics: Channels, Costs, and the Math That Matters

Bard PowerPort case acquisition through paid digital channels is workable right now at costs that justify investment for firms serious about building inventory. Facebook and Instagram remain the primary volume drivers for this tort. The target population is adults, often in the 40 to 65 age range, many of whom are cancer survivors. That demographic indexes well on Facebook, and awareness-style creative that explains the catheter defect without using claimant-recruitment tone converts at reasonable rates.

Realistic cost-per-lead ranges on Facebook sit in the $150 to $400 range depending on creative quality, targeting precision, and landing page efficiency. Cost-per-signed-case, after intake screening and retainer execution, typically runs $1,500 to $3,500 for this tort at current competition levels. Those numbers will move upward as bellwether results generate media attention and more firms enter or expand campaigns.

Search advertising on Google and Bing captures higher-intent traffic but at higher cost per click. The branded and condition-specific search terms for this tort are not yet at the hyper-competitive CPCs seen in torts like mesothelioma or CPAP, which creates an opportunity for firms that invest in search alongside social. Pre-roll video on YouTube can supplement reach for awareness campaigns targeting cancer survivor communities and oncology patient networks.

Creative angles that perform well focus on explaining the fracture and migration mechanism in plain terms, naming the device specifically, and distinguishing it from other port catheters. Many potential claimants had a port catheter but do not know the brand. Creative that walks them through how to confirm device identity drives qualified lead volume and reduces wasted intake effort.

Intake and Qualification: What Makes a Bard PowerPort Case Stick

From the firm's side, intake for this tort requires confirming a few non-negotiable elements. First, device identity. The claimant must have had a Bard PowerPort specifically, not a competitor's port catheter. Other manufacturers use different materials, and their devices are not part of MDL 3081. Medical records confirming the implant, including the device manufacturer and model, are essential. Implant cards, operative reports, and radiology records that reference the device are the standard documentation path.

Second, injury documentation. The qualifying injury categories are catheter fracture, migration, embolism, thrombosis, infection leading to hospitalization, or the need for surgical or interventional removal of catheter fragments. Cases where a patient had a Bard PowerPort removed uneventfully but without documented injury will be harder to place and likely weaker on damages. Firms should prioritize cases with hospital records, imaging confirming migration or fracture, and documented interventions.

Third, timing. Cases should generally fall within applicable statutes of limitation measured from the date of injury discovery or device removal. Intake teams need to confirm this during the initial screen, not after retainer execution.

Retainer flow benefits from e-sign infrastructure and a structured follow-up sequence. This demographic, cancer survivors and their families, often needs more than one touchpoint before signing. Automated follow-up via SMS and email in the 72 hours after initial contact significantly improves conversion rates without adding staff overhead. AI-assisted intake tools that can handle initial qualification calls and document collection are increasingly practical for firms running volume, a topic covered in detail in "A Lawyer's Guide to AI" for firms looking to modernize their intake operations.

How MTAA Runs Bard PowerPort Campaigns

At Mass Tort Ad Agency, we have managed Bard PowerPort case acquisition campaigns alongside our broader portfolio of 100-plus torts and more than $250 million in Facebook ad spend across 600-plus plaintiff firms. We run on a transparent cost-plus model, ad spend plus a 15% fee, with full campaign management including creative, targeting, optimization, and reporting. We do not mark up media spend or take case-referral fees. Firms see exactly what their dollars are doing.

For Bard PowerPort, we are currently running campaigns that are generating signed cases at economics that make sense given the MDL trajectory and the anticipated settlement timeline. The tort is open for campaign investment. Firms that want to understand current lead costs, signing rates, and how their intake process affects downstream case value are welcome to have that conversation directly.

The Window Is Now: Closing Thoughts on Bard PowerPort Case Acquisition

The Bard PowerPort litigation has the structural characteristics plaintiff firms should want in a mass tort investment. A strong internal document record, a large and distributed claimant population, a well-capitalized defendant in Becton Dickinson, an active MDL with bellwether trials on the near-term horizon, and current advertising economics that have not yet been inflated by post-verdict media attention. Bard PowerPort case acquisition at this stage of the MDL is a calculated opportunity, not a speculative one. The firms that build their inventory before the first bellwether verdict will be positioned to benefit the most when settlement discussions eventually begin. Waiting for certainty almost always means paying more and getting in late.